logo-loader
viewIncanthera Ltd

Incanthera says it's making great progress towards commercialisation of lead skin cancer asset

Incanthera's (LON:INC) Simon Ward and Tim McCarthy speak to Proactive following the release of its first set of results since listing earlier this year on the AQSE Growth Market.

CEO ward describes it as a pivotal year for the company and says they're now fully focused on further development of its skin cancer asset, Sol, which is making great progress towards commercialisation.

Quick facts: Incanthera Ltd

Price: 16 GBX

AQSE:INC
Market: AQSE
Market Cap: -
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Incanthera Ltd named herein, including the promotion by the Company of Incanthera Ltd in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Specialist oncology company Incanthera PLC begins trading on NEX

Incanthera PLC's (LON:INC) Tim McCarthy and Simon Ward speak to Proactive's Andrew Scott as the firm began trading on London's NEX Exchange. Incanthera, which is a specialist oncology company focused on transforming cancer treatment, raised £1.2mln as part of the move  from institutional...

on 28/2/20

2 min read